AG
CBAY

Aperio Group’s Cymabay Therapeutics CBAY Stock Holding History

Aperio Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$110K Buy
19,184
+6,842
+55% +$51.8K ﹤0.01% 2375
2020
Q3 		$89K Buy
12,342
+2,235
+22% +$12K ﹤0.01% 2328
2020
Q2 		$35K Sell
10,107
-7,740
-43% -$22.3K ﹤0.01% 2311
2020
Q1 		$26K Sell
17,847
-18,941
-51% -$31.8K ﹤0.01% 2304
2019
Q4 		$73K Buy
36,788
+19,927
+118% +$74.8K ﹤0.01% 2286
2019
Q3 		$87K Buy
16,861
+2,325
+16% +$14.1K ﹤0.01% 2253
2019
Q2 		$104K Buy
+14,536
New +$165K ﹤0.01% 2378

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Aperio Group's CBAY Position: Q4 2020 in Review

Aperio Group increased its Cymabay Therapeutics (CBAY) stake by 55% in Q4 2020, buying an estimated $51.8K and bringing the position to 19,184 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Aperio Group first reported a position in CBAY in Q2 2019 and has held it in 7 quarters since. 145 funds tracked by Wall St. Rank hold CBAY as of Q4 2020.

  • Aperio Group held 19,184 shares of Cymabay Therapeutics worth $110K as of Q4 2020.
  • Aperio Group bought 6,842 Cymabay Therapeutics shares in Q4 2020, an estimated $51.8K.
  • Cymabay Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2375 holding.
  • Aperio Group first reported a position in Cymabay Therapeutics in Q2 2019 and has held it in 7 quarters since.
  • 145 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.